A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy
Condition(s) studied
Investigational drug(s) / intervention(s)
Brogidirsen: Brogidirsen will be administered for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until Brogidirsen is commercially available, whichever is earlier.
Study summary
This Phase 2, open-label, multi-center extension study will be conducted in boys with DMD who completed the 24-week Treatment Period of Study NS-089/NCNP-02-201. Brogidirsen will be administered by IV infusion once weekly for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until brogidirsen is commercially available, whichever is earlier.
Eligibility
Primary outcome measure(s)
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) — Through study completion, an average of 124 weeks
- Change in baseline in the following assessments: 12-lead electrocardiograms (ECGs), Vital signs, Physical and neurological examinations, Clinical laboratory tests — Through study completion, an average of 120 weeks
Trial sites (17)
| Facility | City | Region | Status |
|---|---|---|---|
| Children's Hospital Colorado | Aurora | Colorado | |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | |
| Virginia Commonwealth University Health System | Richmond | Virginia | |
| Queensland Children's Hospital | South Brisbane | Queensland | |
| British Columbia Children's Hospital | Vancouver | British Columbia | |
| London Health Sciences Centre | London | Ontario | |
| Fukui Prefectural Hospital | Fukui-shi | Fukui | |
| NHO Nagara Medical Center | Nagara | Gifu-shi, Gifu | |
| NHO Osaka Toneyama Medical Center | Toyonaka | Osaka | |
| Shiga General Hospital | Moriyama-shi | Shiga | |
| National Center of Neurology and Psychiatry | Kodaira | Tokyo | |
| Starship Children's Hospital | Auckland | New Zealand | |
| Pusan National University Yangsan Hospital | Yangsan | Gyeongsangnam | |
| Seoul National University Hospital | Seoul | South Korea | |
| Ankara Bilkent City Hospital | Ankara | Turkey | |
| Yeditepe University Kosuyolu Hospital | Istanbul | Turkey | |
| S.B.U. Dr. Behcet uz Pediatric Diseases and Surgery Training and Research Hospital | Izmir | Turkey |
More NS Pharma, Inc. trials in Japan
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07943598 on ClinicalTrials.gov ↗ ← All trials in Japan